Protamine Sulfate During Transcatheter Aortic Valve Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02974660

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02974660
Other papers using this trial's data
  • Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) - a single-center, single-blind, randomized placebo-controlled trial Kardiologia polska, 2021 DOI, PubMed 34292562

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02974660. Randomized; single masking; primary purpose prevention. Start 2016-12 (registry gives no type); primary completion 2020-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Protamine Sulfate During Transcatheter Aortic Valve Implantation
Acronym
PS TAVI
Condition
Aortic Valve Stenosis
Intervention (Drug)
Protamine sulfate
Intervention (Drug)
0.9% NaCl
Lead sponsor
Medical University of Warsaw (class: other)

Record details

Record id
cardio:ct-nct02974660
Content hash
ccdcf97ece463dfd308efa39fd9f890d253649d9b44b8d274ef5c703e219f1f9